Literature DB >> 28542980

The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.

Kyung Jin Eoh1, Jung Won Yoon1, Inok Lee1, Jung-Yun Lee1, Sunghoon Kim1, Sang Wun Kim1, Young Tae Kim1, Eun Ji Nam1.   

Abstract

BACKGROUND AND
OBJECTIVE: The therapeutic role of systematic lymph node dissection (LND) remains unclear in advanced epithelial ovarian cancer (EOC), especially during interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NAC). We analyzed the therapeutic and prognostic roles of systematic LND in advanced EOC patients.
METHODS: Data from consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease, who underwent optimal IDS (<1cm) after NAC, were obtained via a retrospective chart review. Patients were classified into a lymph node sampling (LNS; node count <20) group and an LND (node count ≥20) group.
RESULTS: Among 133 study patients, 65 and 68 underwent LND and LNS, respectively, during IDS. Overall survival (OS) was significantly better in the LND group than in the LNS group. In subgroup analysis with negative lymphadenopathy on preoperative imaging, progression-free survival (PFS) and OS were significantly better in the LND group than in the LNS group. Follow-up of subsequent recurrences showed significantly lower nodal and peritoneal recurrence rates among patients who underwent LND. Multivariate analysis identified LND as an independent prognostic factor for PFS and OS.
CONCLUSION: Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  advanced epithelial ovarian cancer; interval debulking surgery; lymphadenectomy; optimal cytoreductive surgery

Mesh:

Substances:

Year:  2017        PMID: 28542980     DOI: 10.1002/jso.24669

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Predictive value of indicator of CA125 combined with D-dimer (ICD) for lymph node metastasis in patients with ovarian cancer: A two center cohort study.

Authors:  Li Zhang; Zongyu Guan; Yi Yin; Chaoyang Ou; Hongyan Qian; Min Tang; Aiguo Shen
Journal:  J Cancer       Date:  2022-05-01       Impact factor: 4.478

Review 2.  Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data.

Authors:  Stephanie Seidler; Meriem Koual; Guillaume Achen; Enrica Bentivegna; Laure Fournier; Nicolas Delanoy; Huyên-Thu Nguyen-Xuan; Anne-Sophie Bats; Henri Azaïs
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

3.  Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer.

Authors:  Minjun He; Yuerong Lai; Hongyu Peng; Chongjie Tong
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

4.  Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis.

Authors:  Giuseppe Caruso; Innocenza Palaia; Giorgio Bogani; Federica Tomao; Giorgia Perniola; Pierluigi Benedetti Panici; Ludovico Muzii; Violante Di Donato
Journal:  J Gynecol Oncol       Date:  2022-07-06       Impact factor: 4.756

5.  Metastasis to para-aortic lymph nodes cephalad to the renal veins in patients with ovarian cancer.

Authors:  Shinichi Komiyama; Masaru Nagashima; Tomoko Taniguchi; Takayuki Rikitake; Mineto Morita
Journal:  World J Surg Oncol       Date:  2020-04-01       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.